ImmunityBio

ANKTIVA NK Cell Therapy Shows 100 Percent Disease Control in Recurrent Glioblastoma – ImmunityBio

ImmunityBio shared a post on X:

”We’ve announced that our initial data shows 100% disease control in 5 out of 5 patients with recurrent glioblastoma after being treated with our ANKTIVA, NK cell therapy plus the Optune Gio device.”

Proceed to the video attached to the post.

More posts featuring ImmunityBio.